Iovance Biotherapeutics approved inducement stock options for 140,860 shares to 27 new non-executive employees on June 18, 2026. The options have an exercise price of $3.91 and vest over three years, rewarding employee retention. This move aligns with Nasdaq Listing Rule 5635(c)(4) and supports Iovance’s growth in cancer therapy innovation. The company continues to advance its tumor infiltrating lymphocyte therapies, including the FDA-approved Amtagvi® for solid tumors.
Ultragenyx Pharmaceutical Inc. awarded 44,409 restricted stock units to 15 newly hired non-executive officers under its Employment Inducement Plan. The grants, approved by the compensation committee, vest over four years with 25% vesting annually, co...
Nyxoah has announced an extraordinary general meeting of shareholders set for July 9, 2026, at its headquarters in Belgium. The meeting will discuss renewing the authorization for the board to increase the company's capital over the next five years, ...
Eupraxia Pharmaceuticals held its Annual General Meeting on June 18, 2026, where shareholders elected all seven board nominees proposed by management with strong majority votes. Additionally, KPMG LLP was reappointed as the company's auditor for the ...
Cate & Chloe is discounting its Bianca 18k Gold-Plated Crystal Hoop Earrings to $19.98 from $86 during Amazon Prime Day 2026, running June 23-26. This 77% markdown aligns with growing consumer demand for affordable luxury jewelry, with earrings price...
AST SpaceMobile (ASTS) is accelerating its satellite launches, aiming to have 45 BlueBird satellites in orbit by the end of the year. The company leverages a strong $3.5 billion cash position to fund over 100 satellites and has secured $1.2 billion i...
